Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
E-Z-Cat Dry
Overview
What is E-Z-Cat Dry?
E-Z-CAT DRY (barium sulfate) is a radiographic
contrast agent that is supplied as white to lightly colored powder
for suspension (40% w/w) with a vanilla aroma for oral administration.
It has a molecular weight of 233.4 g/mol and a density of 4.5 g/cm. The active ingredient barium sulfate is designated
chemically as BaSOwith the following chemical
structure:
E-Z-CAT DRY contains excipients
including: artificial candied sugar flavor, carrageenan, citric acid,
ethyl vanillin, natural and artificial orange flavor, polysorbate
80, saccharin sodium, simethicone, sodium citrate, sodium carboxymethylcellulose,
sorbitol and xanthan gum.
What does E-Z-Cat Dry look like?
-foil-03-14-tx-1417-2-64x150.jpg)
What are the available doses of E-Z-Cat Dry?
For oral suspension: 9 grams of
barium sulfate (40% w/w) in a single-dose pouch for reconstitution
()
What should I talk to my health care provider before I take E-Z-Cat Dry?
How should I use E-Z-Cat Dry?
E-Z-CAT DRY is indicated
for use in computed tomography (CT) of the abdomen to delineate the
gastrointestinal (GI) tract in adult and pediatric patients.
Recommended reconstituted oral dose for adults and pediatric
patients older than 12 years of age is between 450 mL to 900 mL (9
g to 18 g of barium sulfate, respectively) ()
Pediatric patents younger than 12 years of age adjust reconstituted
oral dose based on relative GI volume ()
Must reconstitute supplied powder with water prior to use.
See Full Prescribing Information for reconstitution instructions
()
What interacts with E-Z-Cat Dry?
Sorry No Records found
What are the warnings of E-Z-Cat Dry?
Sorry No Records found
What are the precautions of E-Z-Cat Dry?
Sorry No Records found
What are the side effects of E-Z-Cat Dry?
Sorry No records found
What should I look out for while using E-Z-Cat Dry?
E-Z-CAT DRY is contraindicated in patients with:
- Known or suspected perforation
of the gastrointestinal (GI) tract;- Known obstruction
of the GI tract;- High risk of GI perforation such
as those with a recent prior GI perforation, acute GI hemorrhage or
ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy,
acute GI injury or burn, or recent radiotherapy to pelvis;- High risk of aspiration such as those with prior aspiration,
tracheo-esophageal fistula, or obtundation;- Known
severe hypersensitivity to barium sulfate or any of the excipients
of E-Z-CAT DRY.
What might happen if I take too much E-Z-Cat Dry?
Sorry No Records found
How should I store and handle E-Z-Cat Dry?
Store olanzapine tablets at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Protect olanzapine tablets from light and moisture. Store olanzapine tablets at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Protect olanzapine tablets from light and moisture. 16.1 How SuppliedE-Z-CAT DRY (barium sulfate) for suspension is supplied as a white to lightly colored powder (40 % w/w) in a single-dose foil pouch containing 9 grams of barium sulfate.Provided as: Dispenser Box of 50 x 23 gram foil pouches (NDC 32909-717-01)16.2 Storage and HandlingStore at USP controlled room temperature 20 to 25°C (68 to 77° F).16.1 How SuppliedE-Z-CAT DRY (barium sulfate) for suspension is supplied as a white to lightly colored powder (40 % w/w) in a single-dose foil pouch containing 9 grams of barium sulfate.Provided as: Dispenser Box of 50 x 23 gram foil pouches (NDC 32909-717-01)16.2 Storage and HandlingStore at USP controlled room temperature 20 to 25°C (68 to 77° F).16.1 How SuppliedE-Z-CAT DRY (barium sulfate) for suspension is supplied as a white to lightly colored powder (40 % w/w) in a single-dose foil pouch containing 9 grams of barium sulfate.Provided as: Dispenser Box of 50 x 23 gram foil pouches (NDC 32909-717-01)16.2 Storage and HandlingStore at USP controlled room temperature 20 to 25°C (68 to 77° F).16.1 How SuppliedE-Z-CAT DRY (barium sulfate) for suspension is supplied as a white to lightly colored powder (40 % w/w) in a single-dose foil pouch containing 9 grams of barium sulfate.Provided as: Dispenser Box of 50 x 23 gram foil pouches (NDC 32909-717-01)16.2 Storage and HandlingStore at USP controlled room temperature 20 to 25°C (68 to 77° F).16.1 How SuppliedE-Z-CAT DRY (barium sulfate) for suspension is supplied as a white to lightly colored powder (40 % w/w) in a single-dose foil pouch containing 9 grams of barium sulfate.Provided as: Dispenser Box of 50 x 23 gram foil pouches (NDC 32909-717-01)16.2 Storage and HandlingStore at USP controlled room temperature 20 to 25°C (68 to 77° F).
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Due to its high atomic number, barium (the active ingredient
in E-Z-CAT DRY) is opaque to x-rays and therefore acts as a positive
contrast agent for radiographic studies.
Non-Clinical Toxicology
E-Z-CAT DRY is contraindicated in patients with:- Known or suspected perforation of the gastrointestinal (GI) tract;- Known obstruction of the GI tract;- High risk of GI perforation such as those with a recent prior GI perforation, acute GI hemorrhage or ischemia, toxic megacolon, severe ileus, post GI surgery or biopsy, acute GI injury or burn, or recent radiotherapy to pelvis;- High risk of aspiration such as those with prior aspiration, tracheo-esophageal fistula, or obtundation;- Known severe hypersensitivity to barium sulfate or any of the excipients of E-Z-CAT DRY.
Cisatracurium besylate has been used safely following varying degrees of recovery from succinylcholine-induced neuromuscular block. Administration of 0.1 mg/kg (2 × ED ) cisatracurium besylate at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced ≥ 95% neuromuscular block. The time to onset of maximum block following cisatracurium besylate is approximately 2 minutes faster with prior administration of succinylcholine. Prior administration of succinylcholine had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of cisatracurium besylate. Infusion requirements of cisatracurium besylate in patients administered succinylcholine prior to infusions of cisatracurium besylate were comparable to or slightly greater than when succinylcholine was not administered.
The use of cisatracurium besylate before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
Although not studied systematically in clinical trials, no drug interactions were observed when vecuronium, pancuronium, or atracurium were administered following varying degrees of recovery from single doses or infusions of cisatracurium besylate.
Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of cisatracurium besylate and decrease the required infusion rate of cisatracurium . The magnitude of these effects may depend on the duration of administration of the volatile agents. Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of cisatracurium besylate and therefore, no adjustment to the initial dose should be necessary when cisatracurium besylate is administered shortly after initiation of volatile agents. In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of cisatracurium besylate may be necessary. The average infusion rate requirement may be decreased by as much as 30% to 40%.
In clinical studies propofol had no effect on the duration of action or dosing requirements for cisatracurium besylate.
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as cisatracurium besylate include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. While the effects of chronic phenytoin or carbamazepine therapy on the action of cisatracurium besylate are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
Barium sulfate preparations contain a number of excipients, including natural and artificial flavors and may induce serious hypersensitivity reactions. The manifestations include hypotension, bronchospasm and other respiratory impairments, dermal reactions including rashes, urticaria, and itching. A history of bronchial asthma, atopy, or a previous reaction to a contrast agent may increase the risk for hypersensitivity reactions. Emergency equipment and trained personnel should be immediately available for treatment of a hypersensitivity reaction.
The following adverse reactions have been identified from spontaneous reporting or clinical studies of barium sulfate administered orally. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).